CAC
CELU icon

Cowen and Company’s Celularity CELU Stock Holding History

Cowen and Company’s Portfolio CELU Stock Details CELU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,500
Closed -$275K – 547
2020
Q4 		$275K Sell
2,500
-2,355
-49% -$250K 0.02% 155
2020
Q3 		$510K Buy
+4,855
New +$503K 0.08% 141
2020
Q1 		– Sell
-44,542
Closed -$4.43M – 431
2019
Q4 		$4.43M Buy
44,542
+41,867
+1,565% +$4.15M 0.39% 25
2019
Q3 		$266K Buy
+2,675
New +$262K 0.07% 203

Other funds holding CELU

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Cowen and Company's CELU Position: Q1 2021 in Review

Cowen and Company sold out of Celularity (CELU) in Q1 2021, closing a stake of 2,500 shares — an estimated $275K sold.

Cowen and Company first reported a position in CELU in Q3 2019 and held it in 4 quarters. The position peaked at $4.43M in Q4 2019. 63 funds tracked by Wall St. Rank hold CELU as of Q1 2021.

  • Cowen and Company reported no remaining Celularity position as of Q1 2021 after selling out during the quarter.
  • Cowen and Company sold 2,500 Celularity shares in Q1 2021, an estimated $275K.
  • Cowen and Company first reported a position in Celularity in Q3 2019 and held it in 4 quarters.
  • Cowen and Company's Celularity position peaked at $4.43M in Q4 2019.
  • 63 funds tracked by Wall St. Rank held Celularity as of Q1 2021.

Based on Cowen and Company's 13F filing for Q1 2021, filed 4 May 2021.